510(k) K863317

ENZYGNOST ANTI-VZV IGG TEST by Behring Diagnostics, Inc. — Product Code GQX

K863317 is an FDA 510(k) premarket notification submitted by Behring Diagnostics, Inc. for the device "ENZYGNOST ANTI-VZV IGG TEST". The FDA issued a decision of Substantially Equivalent on April 22, 1987. The device falls under product code GQX (Antiserum, Cf, Varicella-Zoster), a Class II device regulated under 21 CFR 866.3900. Behring Diagnostics, Inc. has at least 10 other 510(k) clearances on record.

Clearance Details

Decision
SESE (Substantially Equivalent)
Decision Date
April 22, 1987
Date Received
August 26, 1986
Clearance Type
Traditional
Expedited Review
No
Third Party Review
No

Device Classification

Device Name
Antiserum, Cf, Varicella-Zoster
Device Class
Class II
Regulation Number
866.3900
Review Panel
MI
Submission Type